TABLE 5.

Multivariate analysis of demographic and clinical characteristics associated with pyrazinamide resistance

Variablec	β	P	OR (95% CI)a
PZA monoresistance vs DS
Previously treated	1.052	0.005b	2.86 (1.363–6.015)
Beijing family	1.186	0.109	3.28 (0.766–14.00)
PZA resistance/MDR vs DS
Age	0.022	0.024b	1.02 (1.003–1.042)
Previously treated	1.867	<0.001b	6.47 (3.186–13.15)
Cavity	0.972	0.008b	2.64 (1.296–5.391)
Beijing family	1.849	0.074	6.35 (0.838–48.14)
PZA resistance vs DS
Age	0.013	0.012b	1.01 (1.003–1.023)
Previously treated	1.193	<0.001b	3.30 (2.131–5.101)
Beijing family	0.812	0.019b	2.25 (1.140–4.451)

^aOR and 95% CI were calculated in the binary logistic regression model by backward selection.

^bP < 0.05.

^cDS, first-line drug susceptible; MDR, multidrug resistant; PZA, pyrazinamide.